0000000000606546

AUTHOR

Giampaolo Muratore

0000-0002-5447-3992

showing 3 related works from this author

Targeting of the Peritumoral Adipose Tissue Microenvironment as an Innovative Antitumor Therapeutic Strategy

2022

The tumor microenvironment (TME) plays a key role in promoting and sustaining cancer growth. Adipose tissue (AT), due to its anatomical distribution, is a prevalent component of TME, and contributes to cancer development and progression. Cancer-associated adipocytes (CAAs), reprogrammed by cancer stem cells (CSCs), drive cancer progression by releasing metabolites and inflammatory adipokines. In this review, we highlight the mechanisms underlying the bidirectional crosstalk among CAAs, CSCs, and stromal cells. Moreover, we focus on the recent advances in the therapeutic targeting of adipocyte-released factors as an innovative strategy to counteract cancer progression.

cancer stem cellstarget therapySettore MED/50 - Scienze Tecniche Mediche ApplicateexosomesBiochemistryadipose tissueNeoplasmsAdipocytesNeoplastic Stem CellsHumanstumor microenvironmentSettore MED/46 - Scienze Tecniche Di Medicina Di LaboratorioMolecular Biologyadipokines
researchProduct

Dual Inhibition of Myc Transcription and PI3K Activity Effectively Targets Colorectal Cancer Stem Cells

2022

Despite advances in the curative approach, the survival rate of advanced colorectal cancer (CRC) patients is still poor, which is likely due to the emergence of cancer cell clones resistant to the available therapeutic options. We have already shown that CD44v6-positive CRC stem cells (CR-CSCs) are refractory toward standard anti-tumor therapeutic agents due to the activation of the PI3K pathway together with high HER2 expression levels. Tumor microenvironmental cytokines confer resistance to CR-CSCs against HER2/PI3K targeting by enhancing activation of the MAPK pathway. Here, we show that the CSC compartment, spared by BRAF inhibitor-based targeted therapy, is associated with increased ex…

cancer stem cellsCancer ResearchOncologySettore MED/04 - PATOLOGIA GENERALECancer stem cellCombination therapies.anti-tumor drug resistanceanti-tumor drug resistance; colorectal cancer; combination therapies; cancer stem cellsNeoplasms. Tumors. Oncology. Including cancer and carcinogenscolorectal cancerSettore MED/46 - Scienze Tecniche Di Medicina Di Laboratoriocombination therapiesRC254-282Cancers
researchProduct

Destroying the Shield of Cancer Stem Cells: Natural Compounds as Promising Players in Cancer Therapy

2022

In a scenario where eco-sustainability and a reduction in chemotherapeutic drug waste are certainly a prerogative to safeguard the biosphere, the use of natural products (NPs) represents an alternative therapeutic approach to counteract cancer diseases. The presence of a heterogeneous cancer stem cell (CSC) population within a tumor bulk is related to disease recurrence and therapy resistance. For this reason, CSC targeting presents a promising strategy for hampering cancer recurrence. Increasing evidence shows that NPs can inhibit crucial signaling pathways involved in the maintenance of CSC stemness and sensitize CSCs to standard chemotherapeutic treatments. Moreover, their limited toxici…

natural productcancer stem cellpolyphenoldrug resistanceSettore MED/50 - Scienze Tecniche Mediche ApplicateflavonoidGeneral MedicineSettore MED/46 - Scienze Tecniche Di Medicina Di Laboratorioalkaloidadjuvant treatmentsJournal of Clinical Medicine
researchProduct